Regeneron Pharmaceuticals

Yahoo Finance • 11 hours ago

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals, Inc. Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urti... Full story

Yahoo Finance • 11 hours ago

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clini... Full story

Yahoo Finance • 11 hours ago

Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants

Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée (UCS) pour les enfants âgés de deux à 11 a... Full story

Yahoo Finance • 13 hours ago

Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies

(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) and Regeneron Pharmaceuticals, Inc. (REGN) have announced a collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies. This partnership brings t... Full story

Yahoo Finance • 17 hours ago

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collaboration combines Telix's expertise in radiopharmaceutical development and manufacturing wi... Full story

Yahoo Finance • 18 hours ago

Jim Cramer on Regeneron (REGN): “I Think The Stock’s Breaking Out Here”

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the stocks Jim Cramer discussed alongside the tech market divide. Toward the end of the lightning round, a caller sought Cramer’s thoughts on the company, and here’s what he had to say... Full story

Yahoo Finance • 3 days ago

Regeneron (REGN): Buy, Sell, or Hold Post Q4 Earnings?

Over the past six months, Regeneron has been a great trade, beating the S&P 500 by 32.3%. Its stock price has climbed to $767, representing a healthy 35.8% increase. This was partly due to its solid quarterly results, and the run-up might... Full story

Yahoo Finance • 3 days ago

Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline

Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering. This report covers the seven major markets (7MM:... Full story

Yahoo Finance • 5 days ago

Regeneron expects ~$102M in Q1 pre-tax IPR&D charges

* Regeneron Pharmaceuticals (REGN [https://seekingalpha.com/symbol/REGN]) expects to record an acquired in-process research and development charge of approximately $102M on a pre-tax basis for the first quarter of 2026. * This charge p... Full story

Yahoo Finance • 7 days ago

FDA Approves Dosing Interval Extension Up To 20 Weeks For EYLEA HD In WAMD And DME

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced that the U.S. Food and Drug Administration (FDA) has approved the extension of dosing intervals for EYLEA HD (Aflibercept) up to every 20 weeks for patients with wet age-related... Full story

Yahoo Finance • 8 days ago

Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus

Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story

Yahoo Finance • 11 days ago

Trump Slaps 100% Tariffs on Some Drug Imports. What to Know.

More than a dozen major drugmakers already have struck ‘most favored nation’ pricing agreements with the White House. Continue Reading... Full story

Yahoo Finance • 11 days ago

No deal yet? Trump readies new tariffs on select drugmakers - report

[Senior woman buying medicine at drugstore] Luis Alvarez The Trump administration plans to impose tariffs on pharmaceutical companies that haven't agreed to lower U.S. drug prices, with an announcement expected as soon as Thursday, _Bloom... Full story

Yahoo Finance • 12 days ago

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 14 days ago

Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins

[Merck headquarters in Kenilworth, New Jersey, August 23, 2022.] JHVEPhoto * New phase 3 data found that Merck's oral PCSK9 inhibitor, enlicitide decanoate, led to greater lowering of low-density lipoprotein cholesterol (LDL-C) compared... Full story

Yahoo Finance • 14 days ago

How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle'

Merck's experimental cholesterol buster easily outperformed a triplet of medications, the Dow Jones component said Monday. Continue Reading... Full story

Yahoo Finance • 14 days ago

Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that focuses on a variety of ailments involving the n... Full story

Yahoo Finance • 14 days ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 16 days ago

Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026.Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 On March 19, 2026, Vertex Pharmaceuticals Incorporated (NA... Full story

Yahoo Finance • 19 days ago

Wells Fargo Raises its Price Target on Amgen (AMGN) to $390 from $375

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 19, 2026, Wells Fargo raised the price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $375 and maintained an Equal Weight rating. The firm high... Full story